 |
Molika Ashford is a GenomeWeb contributing editor and covers personalized medicine and molecular diagnostics. E-mail Molika Ashford. |
AB Science, Skuldtech Developing Companion Dx to Predict Masitinib Response in Pancreatic Cancer
November 14, 2012
AB Science, Skuldtech Developing Companion Dx to Predict Masitinib Response in Pancreatic Cancer
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Skuldtech, AB Science to Develop CDx for Pancreatic Cancer Drug
November 5, 2012 / GenomeWeb Daily News - PrimeraDx Bolsters CDx Development Efforts with Quest Diagnostics Agreement
March 28, 2013 / PCR Insider - Trovagene, MD Anderson Partner on Transrenal BRAF Mutation Detection
January 3, 2013 / PCR Insider - Trovagene Set to Offer Transrenal KRAS Assay on Bio-Rad dPCR System in January
November 29, 2012 / PCR Insider - SomaGenics to Use $300,000 NCI Grant to Develop PCR Method for Fragmented mRNA in FFPE Samples
September 27, 2012 / PCR Insider